Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FSHR | P23945 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16130200 | 0.94 | TLR2 (0.38) | HPGDROCK2KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL51812 | 0.91 | HPGD (0.35) | HPGDROCK2KDM4ESMN1; SMN2RORC | |
| SCHEMBL9905103 | 0.91 | RORC (0.36) | RORCTSHRFSHRADORA2AADORA1 | |
| SCHEMBL61886 | 0.91 | HPGD (0.38) | HPGDROCK2KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL52246 | 0.90 | HPGD (0.37) | HPGDROCK2KDM4EL3MBTL1MAPT | |
| SCHEMBL63542 | 0.90 | HPGD (0.38) | HPGDROCK2KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL14214193 | 0.88 | TSHR (0.36) | MAPTRORCTSHRFSHR | |
| SCHEMBL14214194 | 0.87 | TSHR (0.38) | L3MBTL1SMN1; SMN2MAPTRORCTSHR | |
| SCHEMBL61903 | 0.87 | ROCK2 (0.36) | HPGDROCK2KDM4ESMN1; SMN2RORC | |
| SCHEMBL9921561 | 0.86 | TLR2 (0.38) | L3MBTL1MAPTRORCTSHRFSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846659-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2649074-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120309745-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| WO-2012078844-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309745-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | HPGD 1406/4885ROCK2 1690/4885KDM4E 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.